Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Breast Neoplasms 2Vomiting 1Uterine Cervical Neoplasms 1Trigger Finger Disorder 1Sarcoma, Alveolar Soft Part 1Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Pain 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoplasm Metastasis 1Nausea 1Mucositis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Mast-Cell 1Leukemia, Hairy Cell 1

Interventions

Cyclophosphamide 6Rituximab 3isatuximab 2fludarabine phosphate 2fludarabine 2durvalumab 2anlotinib 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Sunitinib 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Pemetrexed 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Lenalidomide 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cisplatin 2Carboplatin 2Busulfan 2Bevacizumab 2130-nm albumin-bound paclitaxel 2ponatinib 1pomalidomide 1penpulimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms by Histologic Type × Acetaminophen × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡